EGFR and cancer: According to national comprehensive cancer network (NCCN) guidelines 2021, first-line treatment of driver mutation includes the use of EGFR inhibitor line erlotinib which may be combined with bevacizumab, a VEGF antagonist for a few years followed by a biopsy, if cancer continues to grow.6 However, in our case EGFR mutation was negative.